475830.KQ KOE
Orum Therapeutics, Inc.
1W: -15.4%
1M: -64.3%
3M: -63.4%
YTD: -81.6%
1Y: -9.2%
₩21,150.00 ($15.77)
-2200.00 (-9.42%)
Weekly Expected Move ±20.3%
₩12543
₩16846
₩21150
₩25454
₩29757
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap₩449.1B ($334.8M)
52W Range20850-146600
Volume541,140
Avg Volume253,129
Beta0.46
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOSung-Joo Lee
Employees21
SectorHealthcare
IndustryBiotechnology
IPO Date2025-02-14
Websiteorumrx.com
281-25 Munji-ro
Daejeon, DE 34050
KR
Daejeon, DE 34050
KR
82 4 2716 3030
About Orum Therapeutics, Inc.
Orum Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions for both cancer and immune system conditions. The firm specializes in creating degrader-antibody conjugates, an innovative class of drugs that merges traditional antibody-drug conjugate (ADC) technology with targeted protein degradation. Their flagship product candidate, ORM-1153, functions as a GSPT1 protein degrader, specifically engineered to address hematologic malignancies. Orum Therapeutics was established in 2016 and operates out of Daejeon, South Korea.
Latest News
No recent news
Recent Insider Trades
No insider trades found